Ivonescimab Meets Overall Survival Key Secondary Endpoint in Interim Analysis of Phase III HARMONi-2 Study, Demonstrating Statistically Significant and Clinically Meaningful Benefit Versus Pembrolizumab in First-Line PD-L1-Positive NSCLC

Akeso announced that a pre-specified interim analysis of overall survival (OS) in the HARMONi-2 (AK112-303) trial, assessed by the IDMC, met the key criterion. The update is a supportive clinical milestone for AK112-303, though the article excerpt does not provide effect size or timing. Net impact is modestly positive given the probability of favorable efficacy momentum into later analyses.